Triptorelin Pamoate API is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) engineered for high-affinity receptor binding in preclinical experimental protocols. Available as a research-grade raw compound, it enables investigators to analyze pituitary receptor desensitization, endocrine signaling cascades, and receptor turnover in controlled laboratory environments. PX1 Research provides fully characterized, USA-manufactured material backed by comprehensive lot-specific analytical documentation.
Triptorelin Pamoate API is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) engineered for high-affinity receptor binding in preclinical experimental protocols. Available as a research-grade raw compound, it enables investigators to analyze pituitary receptor desensitization, endocrine signaling cascades, and receptor turnover in controlled laboratory environments. PX1 Research provides fully characterized, USA-manufactured material backed by comprehensive lot-specific analytical documentation.
Triptorelin Pamoate API (Active Pharmaceutical Ingredient) is a high-purity, synthetic decapeptide analogue of natural gonadotropin-releasing hormone (GnRH), combined with pamoic acid to form a low-solubility salt. Supplied strictly for laboratory research and in vitro experimentation, it is utilized by scientists to study GnRH receptor super-agonism, gonadotropin suppression kinetics, and endocrine pathways.
As a primary reference compound in basic science, triptorelin pamoate active ingredient exhibits significantly higher binding affinity and enzymatic resistance compared to native hypothalamic LHRH/GnRH. In vitro and animal model data demonstrate that initial exposure triggers transient gonadotropin release, followed by sustained down-regulation of pituitary GnRH receptors. Researchers utilize this API to model long-term hormone deprivation and evaluate target tissue responses without confounding variables from inconsistent material purities.
Chemically designated as [D-Trp6]LHRH pamoate salt, triptorelin contains a specific D-amino acid substitution at position 6 of the decapeptide sequence: Pyro-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2. The inclusion of D-tryptophan increases hydrophobic interactions within the GnRH receptor binding pocket and renders the backbone resistant to endopeptidase degradation.
The molecular formula of the peptide core is C64H82N18O13, paired with pamoic acid (embonic acid, C23H16O6) to form a 1:1 or stoichiometric salt complex. This specific salt modification alters aqueous solubility dynamics, providing a stable baseline for formulating sustained-release vehicles in preclinical pharmacokinetic assays. Researchers studying chemical stability can compare this molecule against other synthetic structures within our complete research peptide catalog.
In preclinical model systems, triptorelin pamoate functions as a potent super-agonist of the G-protein coupled GnRH receptor (GnRH-R) situated on pituitary gonadotrope cells. Upon binding, the agonist initially stimulates the phospholipase C (PLC) signal transduction cascade, inducing an influx of intracellular calcium and stimulating transient expression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
However, persistent occupancy of the receptor by triptorelin leads to rapid uncoupling from G-proteins, endocytosis of the receptor complex, and subsequent desensitization of downstream signaling. Preclinical studies suggest that within 7 to 14 days of continuous exposure in rodent models, circulating gonadotropins and downstream gonadal steroids drop to castrate levels. Investigators leverage this predictable biphasic profile to examine cellular adaptations to severe, prolonged endocrine blockade.
When designing comparative endocrine trials, researchers frequently evaluate triptorelin alongside related synthetic GnRH agonists, such as leuprolide acetate, goserelin acetate, and buserelin. While all four compounds share the core LHRH backbone and exhibit super-agonist behavior, key structural variations at positions 6, 9, and 10 create distinct receptor affinity, bio-half-life, and solubility profiles.
Triptorelin’s D-Trp6 modification provides higher receptor binding affinity ($K_d \approx 0.2\text{ nM}$) in isolated cell membrane preparations than leuprolide's D-Leu6 substitution. Furthermore, the pamoate salt form of triptorelin exhibits markedly reduced water solubility compared to the acetate salts of leuprolide or goserelin. This physical characteristic makes triptorelin pamoate API the preferred reference standard when evaluating hydrophobic matrix encapsulation, microparticle formulations, or extended-release depot delivery systems in preclinical research. Scientists exploring signal transduction patterns can reference our dedicated GnRH pathway research library for comparative baseline data.
In vitro research frequently utilizes triptorelin pamoate API to probe direct, non-pituitary actions on peripheral tissue lines. Multiple studies have identified functional GnRH receptors expressed on hormone-sensitive cell lines, including LNCaP (prostate), MCF-7 (breast), and OVCAR-3 (ovarian) models. In these systems, administration of micro-molar concentrations of triptorelin allows scientists to investigate direct anti-proliferative signaling, activation of apoptotic pathways, and modulation of growth factor receptor cross-talk.
In animal models, triptorelin pamoate serves as an essential tool for establishing controlled hypogonadism. This enables investigators to model bone density loss, metabolic shifts, cardiovascular changes, and tumor regression dynamics under strict hormonal suppression. Having access to active pharmaceutical ingredient (API) grade purity ensures that observational changes in animal physiology are directly attributable to the peptide mechanism rather than trace impurities or bacterial contaminants.
Due to the presence of the pamoate salt counter-ion, triptorelin pamoate exhibits low solubility in pure water or neutral aqueous buffers (e.g., standard PBS). For in vitro cell culture protocols, the raw API powder should first be solubilized in organic solvents such as dimethyl sulfoxide (DMSO) or dimethylformamide (DMF) to create a concentrated stock solution.
Once completely dissolved in DMSO, the stock can be diluted into culture media or working buffer arrays, maintaining a final organic solvent concentration below 0.1% v/v to eliminate vehicle cytotoxicity. Lyophilized API stock should be stored at -20°C in a desiccated environment protected from light. Reconstituted liquid stock solutions in DMSO are stable when aliquoted and stored at -80°C, avoiding repeated freeze-thaw cycles that can induce peptide bond cleavage.
Evaluating API-grade raw materials requires rigorous analytical validation. Synthetic peptide synthesis can introduce truncation sequences, deletion peptides, and chemical adducts. PX1 Research subjects every batch of Triptorelin Pamoate API to comprehensive multi-tier testing in ISO 17025 accredited analytical facilities.
Purity is quantified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum baseline purity of 98.0%. Molecular identity is verified via Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact monoisotopic mass. Furthermore, because bacterial pyrogens can compromise cell viability and animal model immune responses, every lot undergoes chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain strictly below 0.01 EU/mg.
Selecting a reliable supplier for peptide APIs requires consistent batch-to-batch reproducibility, transparent analytical documentation, and compliant manufacturing infrastructure. PX1 Research manufactures all research compounds within state-of-the-art facilities located in California and Arizona, adhering to strict quality controls.
Every shipment of Triptorelin Pamoate API includes a lot-specific Certificate of Analysis (COA) containing raw HPLC chromatograms and mass spectra. Industrial research labs, university departments, and contract research organizations requiring multi-gram or kilogram quantities for high-throughput screening can establish streamlined procurement protocols through our dedicated bulk research accounts.
What is the primary difference between Triptorelin Pamoate API and Triptorelin Acetate?
The primary difference lies in the salt form counter-ion. Triptorelin acetate uses an acetate salt, which is highly soluble in water, whereas triptorelin pamoate uses a pamoate (embonic acid) salt, which yields low aqueous solubility. The pamoate salt is typically selected for extended-release formulations and matrix interaction studies in preclinical research.
Is Triptorelin Pamoate API supplied for human administration?
No. Triptorelin Pamoate API from PX1 Research is strictly designated as a research compound for in vitro, biochemical, and preclinical laboratory experimentation. It is not for human use, therapeutic administration, or veterinary clinical application.
How should Triptorelin Pamoate API be reconstituted for in vitro cell assays?
Because of its pamoate salt structure, the API has minimal solubility in plain aqueous buffers. It should first be dissolved in high-purity DMSO to create a master stock solution. That stock solution can then be diluted into culture media, keeping final DMSO concentrations below 0.1% to avoid cell toxicity.
What purity level is guaranteed for PX1 Research Triptorelin Pamoate API?
PX1 Research guarantees a minimum purity of 98.0% as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). Exact purity percentages and mass spectrometry validation are reported on the lot-specific COA included with every order.
Are endotoxin levels tested for this raw API material?
Yes. Every batch undergoes kinetic chromogenic LAL testing to verify that bacterial endotoxin levels remain below 0.01 EU/mg, preventing pyrogenic interference in preclinical tissue and animal models.
What temperature conditions are recommended for long-term API storage?
Lyophilized Triptorelin Pamoate API powder should be stored long-term at -20°C or -80°C in a dry container sealed with a desiccant, protected from direct light. Avoid exposing unopened vials to ambient room humidity prior to temperature equilibration.
Can PX1 Research supply Triptorelin Pamoate API in bulk quantities for large-scale studies?
Yes. PX1 Research supports high-throughput laboratory screening and large-scale academic or industrial research projects. Custom packaging and bulk synthesis options are available by submitting a request through our wholesale portal.
How does Triptorelin compare in affinity to native GnRH?
Preclinical receptor binding assays demonstrate that Triptorelin exhibits approximately 100-fold higher binding affinity for the pituitary GnRH receptor compared to native, unmodified GnRH, primarily due to the metabolic resistance provided by the D-Trp6 substitution.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.